<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00759304</url>
  </required_header>
  <id_info>
    <org_study_id>9808112</org_study_id>
    <nct_id>NCT00759304</nct_id>
  </id_info>
  <brief_title>Evaluation of Aging, Autonomic Nervous System Activity and Cardiovascular Events</brief_title>
  <acronym>PROOF</acronym>
  <official_title>Evaluation of Aging, Autonomic Nervous System Activity and Cardiovascular Events on a Prospective Cohort of Subjects Aged 65 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The regulatory effects of the autonomic nervous system (ANS) concern almost all organs which
      permanently feed information back to this global biological vigilance system controlling
      allostasis. Heart rate fluctuations are highly dependent on ANS control, making the heart one
      of the best indicators of ANS activity.

      Low ANS activity level is associated with severe cardiac and cerebral events, as well as to
      death from any cause in the general population.

      This PROOF study was hence designed to evaluate ANS activity levels among a healthy retired
      population, but should these levels decline overtime, to use this as a predictor of
      cardiovascular and cerebrovascular events, taking into account established cardiovascular
      risk factors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main goal of this PROOF study is to evaluate, on a selected prospective cohort of
      subjects aged 65 years upon study entry, the prognostic values of ANS activity levels
      measured at preset times, and more specifically, of its decline over the follow-up period,
      for fatal and non-fatal cardiovascular and cerebrovascular events.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2, 2000</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite criterion : fatal and non-fatal cardiovascular or cerebrovascular events</measure>
    <time_frame>During all the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence and severity of clinically silent stroke revealed through brain MRI</measure>
    <time_frame>Years 1, 3 and 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological performance</measure>
    <time_frame>Years 1, 3 and 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANS activity measured by heart rate variability + spontaneous baroreflex + blood pressure variability</measure>
    <time_frame>Years 1, 3 and 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological data : fasting blood glucose, total and HDL cholesterol, triglycerides and CRP</measure>
    <time_frame>Years 1, 3 and 5</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1011</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PROOF cohort</arm_group_label>
    <description>Healthy inhabitants of the city of Saint-Etienne, France, and aged 65 years at the inclusion date.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects were recruited amongst the inhabitants of the city of Saint-Etienne, France, and
        were eligible if aged 65 at the inclusion date.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  65 years old

          -  informed consent signed

        Exclusion Criteria:

          -  prior myocardiac infarction

          -  prior stroke

          -  hearth failure

          -  atrial fibrillation

          -  insulin-treated diabetes mellitus

          -  cardiac pacemaker

          -  disease limiting life expectancy to &lt; 5 years

          -  contraindication to brain MRI

          -  living in an institution
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude BARTHELEMY, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier de Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Roche F, Gaspoz JM, Da Costa A, Isaaz K, Duverney D, Pichot V, Costes F, Lacour JR, Barthélémy JC. Frequent and prolonged asymptomatic episodes of paroxysmal atrial fibrillation revealed by automatic long-term event recorders in patients with a negative 24-hour Holter. Pacing Clin Electrophysiol. 2002 Nov;25(11):1587-93.</citation>
    <PMID>12494616</PMID>
  </reference>
  <reference>
    <citation>Pichot V, Buffière S, Gaspoz JM, Costes F, Molliex S, Duverney D, Roche F, Barthélémy JC. Wavelet transform of heart rate variability to assess autonomic nervous system activity does not predict arousal from general anesthesia. Can J Anaesth. 2001 Oct;48(9):859-63.</citation>
    <PMID>11606341</PMID>
  </reference>
  <results_reference>
    <citation>Barthélémy JC, Pichot V, Dauphinot V, Celle S, Laurent B, Garcin A, Maudoux D, Kerleroux J, Lacour JR, Kossovsky M, Gaspoz JM, Roche F. Autonomic nervous system activity and decline as prognostic indicators of cardiovascular and cerebrovascular events: the 'PROOF' Study. Study design and population sample. Associations with sleep-related breathing disorders: the 'SYNAPSE' Study. Neuroepidemiology. 2007;29(1-2):18-28.</citation>
    <PMID>17898520</PMID>
  </results_reference>
  <results_reference>
    <citation>Gosse P, Roche F, Dauphinot V, Maudoux D, Pichot V, Barthelemy JC. Components of arterial stiffness in a population of 65-year-old subjects: PROOF study. J Hypertens. 2008 Jun;26(6):1138-46. doi: 10.1097/HJH.0b013e3282fa142b.</citation>
    <PMID>18475151</PMID>
  </results_reference>
  <results_reference>
    <citation>Rouch I, Anterion CT, Dauphinot V, Kerleroux J, Roche F, Barthelemy JC, Laurent B. Cognitive complaints, neuropsychological performance and affective disorders in elderly community residents. Disabil Rehabil. 2008;30(23):1794-802. doi: 10.1080/09638280701667825.</citation>
    <PMID>18608410</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2008</study_first_submitted>
  <study_first_submitted_qc>September 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aging</keyword>
  <keyword>cardiovascular risk factors</keyword>
  <keyword>Autonomic nervous system</keyword>
  <keyword>stroke</keyword>
  <keyword>Myocardiac infarction</keyword>
  <keyword>Neuropsychological evaluation</keyword>
  <keyword>Prospective cohort</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

